Subscribe to Newsletter

Bioprocessing - Upstream & Downstream

Manufacture Bioprocessing - Upstream & Downstream

Respecting the Role of the CDMO in the mRNA Era

| Eunseo Lee | 5 min read

mRNA therapeutics are a hot development trend, but with expertise and experience in short supply, who are the unsung heroes?

Manufacture Bioprocessing - Upstream & Downstream

Processing the Future

| Sponsored by Asahi Kasei

In this eBook, experts from Asahi Kasei Bioprocess discuss key areas of bioprocessing.

Manufacture Bioprocessing - Upstream & Downstream

Propelling the Promise of mRNA

| Rob Coker | 4 min read

With mRNA technology scooping the 2023 Nobel Prize for Medicine, demand is growing. Can CDMOs keep up?

Manufacture Advanced Medicine

Got You Covered

| Stephanie Vine | 3 min read

From flu vaccines, to gene editing, to antibody drug conjugates, and women’s careers; we look back on our 2023 magazine covers.

Manufacture Bioprocessing - Upstream & Downstream

Modelling The Future Of Lyophilization

| Brecht Vanbillemont, Andrea Arsiccio | 3 min read

Academia suggests we need to upgrade lyophilization, but scientists are being slow to respond

Manufacture Bioprocessing - Upstream & Downstream

The Case for MMC

| Heidi Jones | 8 min read

The use of multimodal chromatography is increasing in biopharma purification processes. Here’s why.

Manufacture Bioprocessing - Upstream & Downstream

Say No to Subpar Slurry Preparation

| Sponsored by Asahi Kasei | 6 min read

Discover how Asahi Kasei Bioprocess is engineering a streamlined approach to chromatography media preparation.

Manufacture Bioprocessing - Upstream & Downstream

Less Patience, More Patients

| 4 min read

Sitting Down With Dick Sundh, General Manager, Kite Pharma

Manufacture Bioprocessing - Upstream & Downstream

Getting More from Your Buffer Management Strategy

| Sponsored by Asahi Kasei Bioprocess | 7 min read

We delve into the story behind Lonza’s collaboration with Asahi Kasei Bioprocess America.

Manufacture Bioprocessing - Upstream & Downstream

Planes, Trains, and Autologous Therapies

| Sumukhi Sreevatsan | 3 min read

The potential of the cell and gene therapies sector depends – partially – on the expertise of the transport and logistics partners that complement it.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register